Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies
Malaria, an infection caused by apicomplexan parasites of the genus Plasmodium, continues to exact a significant toll on public health with over 200 million cases world-wide, and annual deaths in excess of 600,000. Considerable progress has been made to reduce malaria burden in endemic countries in...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2022
|
| _version_ | 1797110492045508608 |
|---|---|
| author | Nacer, A Kivi, G Pert, R Juronen, E Holenya, P Aliprandini, E Amino, R Silvie, O Quinkert, D Le Duff, Y Hurley, M Reimer, U Tover, A Draper, SJ Gilbert, S Ho, MM Bowyer, PW |
| author_facet | Nacer, A Kivi, G Pert, R Juronen, E Holenya, P Aliprandini, E Amino, R Silvie, O Quinkert, D Le Duff, Y Hurley, M Reimer, U Tover, A Draper, SJ Gilbert, S Ho, MM Bowyer, PW |
| author_sort | Nacer, A |
| collection | OXFORD |
| description | Malaria, an infection caused by apicomplexan parasites of the genus Plasmodium, continues to exact a significant toll on public health with over 200 million cases world-wide, and annual deaths in excess of 600,000. Considerable progress has been made to reduce malaria burden in endemic countries in the last two decades. However, parasite and mosquito resistance to frontline chemotherapies and insecticides, respectively, highlights the continuing need for the development of safe and effective vaccines. Here we describe the development of recombinant human antibodies to three target proteins from Plasmodium falciparum: reticulocyte binding protein homologue 5 (PfRH5), cysteine-rich protective antigen (PfCyRPA), and circumsporozoite protein (PfCSP). All three proteins are key targets in the development of vaccines for blood-stage or pre-erythrocytic stage infections. We have developed potent anti-PfRH5, PfCyRPA and PfCSP monoclonal antibodies that will prove useful tools for the standardisation of assays in preclinical research and the assessment of these antigens in clinical trials. We have generated some very potent anti-PfRH5 and anti-PfCyRPA antibodies with some clones >200 times more potent than the polyclonal anti-AMA-1 antibodies used for the evaluation of blood stage antigens. While the monoclonal and polyclonal antibodies are not directly comparable, the data provide evidence that these new antibodies are very good at blocking invasion. These antibodies will therefore provide a valuable resource and have potential as biological standards to help harmonise pre-clinical malaria research. |
| first_indexed | 2024-03-07T07:57:05Z |
| format | Journal article |
| id | oxford-uuid:2837d9f1-6503-4738-963c-abe699044b51 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:57:05Z |
| publishDate | 2022 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:2837d9f1-6503-4738-963c-abe699044b512023-08-24T14:57:30ZExpanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodiesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2837d9f1-6503-4738-963c-abe699044b51EnglishSymplectic ElementsFrontiers Media2022Nacer, AKivi, GPert, RJuronen, EHolenya, PAliprandini, EAmino, RSilvie, OQuinkert, DLe Duff, YHurley, MReimer, UTover, ADraper, SJGilbert, SHo, MMBowyer, PWMalaria, an infection caused by apicomplexan parasites of the genus Plasmodium, continues to exact a significant toll on public health with over 200 million cases world-wide, and annual deaths in excess of 600,000. Considerable progress has been made to reduce malaria burden in endemic countries in the last two decades. However, parasite and mosquito resistance to frontline chemotherapies and insecticides, respectively, highlights the continuing need for the development of safe and effective vaccines. Here we describe the development of recombinant human antibodies to three target proteins from Plasmodium falciparum: reticulocyte binding protein homologue 5 (PfRH5), cysteine-rich protective antigen (PfCyRPA), and circumsporozoite protein (PfCSP). All three proteins are key targets in the development of vaccines for blood-stage or pre-erythrocytic stage infections. We have developed potent anti-PfRH5, PfCyRPA and PfCSP monoclonal antibodies that will prove useful tools for the standardisation of assays in preclinical research and the assessment of these antigens in clinical trials. We have generated some very potent anti-PfRH5 and anti-PfCyRPA antibodies with some clones >200 times more potent than the polyclonal anti-AMA-1 antibodies used for the evaluation of blood stage antigens. While the monoclonal and polyclonal antibodies are not directly comparable, the data provide evidence that these new antibodies are very good at blocking invasion. These antibodies will therefore provide a valuable resource and have potential as biological standards to help harmonise pre-clinical malaria research. |
| spellingShingle | Nacer, A Kivi, G Pert, R Juronen, E Holenya, P Aliprandini, E Amino, R Silvie, O Quinkert, D Le Duff, Y Hurley, M Reimer, U Tover, A Draper, SJ Gilbert, S Ho, MM Bowyer, PW Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies |
| title | Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies |
| title_full | Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies |
| title_fullStr | Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies |
| title_full_unstemmed | Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies |
| title_short | Expanding the malaria antibody toolkit: development and characterisation of Plasmodium falciparum RH5, CyRPA, and CSP recombinant human monoclonal antibodies |
| title_sort | expanding the malaria antibody toolkit development and characterisation of plasmodium falciparum rh5 cyrpa and csp recombinant human monoclonal antibodies |
| work_keys_str_mv | AT nacera expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT kivig expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT pertr expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT juronene expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT holenyap expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT aliprandinie expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT aminor expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT silvieo expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT quinkertd expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT leduffy expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT hurleym expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT reimeru expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT tovera expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT drapersj expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT gilberts expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT homm expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies AT bowyerpw expandingthemalariaantibodytoolkitdevelopmentandcharacterisationofplasmodiumfalciparumrh5cyrpaandcsprecombinanthumanmonoclonalantibodies |